Drugs / HSK44459
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06858657 | Aug → Nov 2024 | — | Haisco Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07623486 | May 2026 → Mar 2027 expected | psoriasis | Haisco Pharmaceutical Group Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT07150988 | Sep 2025 → Nov 2026 expected | psoriasis | Haisco Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07070739 | Jul 2025 → Jul 2027 expected | Behcet disease | Haisco Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07019090 | Jun 2025 → Oct 2026 expected | idiopathic pulmonary fibrosis | Haisco Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06996912 | May 2025 → Jan 2026 overdue | atopic eczema | Xizang Haisco Pharmaceutical Co., Ltd | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06902428 | Mar 2025 → Jun 2026 overdue | Behcet disease | Haisco Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06764862 | Jan 2025 → Feb 2026 | idiopathic pulmonary fibrosis | Haisco Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07503587 | Apr 2026 → Dec 2028 expected | pulmonary fibrosis | Haisco Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07519070 | Apr 2026 → Apr 2028 expected | idiopathic pulmonary fibrosis | Haisco Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HSK44459 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07519070 ↗ |
| Route | Oral | “HSK44459 taken orally” NCT06764862 ↗ |